Skip to text Skip to main menu

SCIENCE & TECHNOLOGY

ABBIO’S CORE TECHNOLOGIES : (ADVANCED) sCAR-T TECH

Advanced sCAR-T technology

Generation of Epitope Spreading

The treatment for heterogeneous solid tumors demands various SMs targeting multiple TAAs and advanced sCAR-T capable of inducing epitope spreading. To create impactful immunotherapeutic modality for the solid tumor, we are developing advanced sCAR-T and SMs through the close collaboration with our partners.

Strong in vivo Persistence

We also aim to secure a technical tool to enhance the in vivo persistence of sCAR-T cells by promoting their differentiation into stem cell-like memory T cell, paving the way for more effective treatments of hematologic malignancies and solid tumors.

  • Current T Cell Engager
    (TCE), mAb
    • Immune signaling via the IS
      +
    • Adverse effect
      +
    • T cell exhaustion
      +
    • Switch off
      x
    • Flexibility
      (the ability of targeting multiple TAAs)
      ?
    • Epitope spreading
      x
    TCE : Recruitment of pan-T cells

    Activation of counterproductive CD3+ T cell subsets (e.g., Tregs, naïve T cells, exhausted T cells, CD4+ T cells secreting excessive amounts of various cytokines), may reduce anti-tumor efficacy of TCE.

  • Conventional CAR-T
    • Immune signaling via the IS
      ++++
    • Adverse effect
      ++++
    • T cell exhaustion
      ++++
    • Switch off
      x
    • Flexibility
      (the ability of targeting multiple TAAs)
      x
    • Epitope spreading
      x
  • (a)sCAR-T
    • Immune signaling via the IS
      +++
    • Adverse effect
      +/-
    • T cell exhaustion
      +/-
    • Switch off
      O
    • Flexibility
      (the ability of targeting multiple TAAs)
      O
    • Epitope spreading
      O